Clinical Data GSK hails ‘unprecedented’ cure rates with hep B drug PharmaphorumThe B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.Infectious DiseaseRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) Pharmaphorum The B-Well trials of GSK’s bepirovirsen position the antisense drug as a “major step towards a cure for hepatitis B infection,” according to experts. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancerNext: France ‘first EU country to cover obesity drugs’ Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
